Vical

News

Vical slashes staff after culling phase II antifungal

US biotech Vical is planning another round of job cuts after deciding to abandon its antifungal drug VL-2397, its last remaining clinical-stage asset.

News

GSK planning 1,200 job cuts in Belgium, says paper

GSK is said to be preparing to cut around 1,200 positions from its workforce in Belgium as part of a cost-saving programme launched by CEO Luke Miels.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks